Immunotherapy Shows Promise for Treating Depression in Early Trial

Potential relief for patients with treatment-resistant depression who currently lack effective therapeutic options.

For generations, depression has been mapped onto the language of brain chemistry — a deficit here, an imbalance there. But early clinical findings now suggest that for some patients, the deeper disturbance may lie not in neurotransmitters but in the immune system itself, as an arthritis drug targeting inflammatory protein IL-6 appears to ease severe depression in those for whom conventional treatments have offered no relief. This quiet reframing — from mood disorder to inflammatory condition — may be one of the more consequential shifts in psychiatric thinking in decades, carrying particular w

Immunotherapy Shows Promise for Treating Depression in Early Trial

Cobertura Relacionada

Receba o Register no seu e-mail